EphemerisXResearch

Complete Response Letters

Milestone Pharmaceuticals USA, Inc.: etripamil

What FDA's Complete Response Letters to the company say, in the letters' own words.

EphemerisX Research · Sep 30, 2026 · Sources: FDA, SEC

Complete Response Letter, Mar 27, 2025

We reserve further comment on the proposed labeling until the application is otherwise adequate.
Complete Response Letter · Mar 27, 2025 · p. 2Open the letter at p. 2 ↗CRL_NDA218571_20250327:p1:s25

More Complete Response Letters

All companies in the CRL Tracker →

Updated Sep 30, 2026 · built from 283 companies in the EphemerisX knowledge graph. This page is regenerated as companies are added.